Gamble by Takeda on unproven cancer mechanism draws a blankTakeda says a phase 3 trial of its cancer candidate pevonedistat – a class-leading NEDD8-activating enzyme inhibitor – Share XGamble by Takeda on unproven cancer mechanism draws a blankhttps://pharmaphorum.com/news/takeda-gamble-on-unproven-cancer-mechanism-draws-a-blank/
Servier gets a win for cancer drug Tibsovo, bought in $1.8bn Agios dealJust three months after completing its $1.8 billion takeover of Agios’ oncology pipeline, Servier has reported positive results Share XServier gets a win for cancer drug Tibsovo, bought in $1.8bn Agios dealhttps://pharmaphorum.com/news/servier-gets-a-win-for-cancer-drug-tibsovo-bought-in-1-8bn-agios-deal/
EU okays BMS’ azacitidine pill for first-line maintenance of AMLBristol-Myers Squibb has been granted EU approval for Onureg (azacitidine), a tablet form of an intravenous drug that Share XEU okays BMS’ azacitidine pill for first-line maintenance of AMLhttps://pharmaphorum.com/news/eu-okays-bms-azacitidine-pill-for-first-line-maintenance-of-aml/
J&J backs out of $1.6bn blood cancer antibody alliance with ArgenxBelgian biotech Argenx has lost its development partner for acute myeloid leukaemia antibody cusatuzumab, after Johnson & Johnson Share XJ&J backs out of $1.6bn blood cancer antibody alliance with Argenxhttps://pharmaphorum.com/news/jj-backs-out-of-1-6bn-blood-cancer-antibody-alliance-with-argenx/
Rubius launches $200m IPO to fund red blood cell therapiesRubius Therapeutics has announced the pricing of its Nasdaq IPO, aiming to raise $200 million towards its novel Share XRubius launches $200m IPO to fund red blood cell therapieshttps://pharmaphorum.com/news/rubius-launches-200m-ipo-for-red-blood-cell-therapies/
FDA grants full approval for Roche/AbbVie’s Venclexta in AML combination therapiesCombination therapies involving Roche and AbbVie’s cancer drug Venclexta have been formally approved by the FDA in acute Share XFDA grants full approval for Roche/AbbVie’s Venclexta in AML combination therapieshttps://pharmaphorum.com/news/fda-grants-full-approval-for-roche-abbvies-venclexta-in-aml-combination-therapies/
NICE backs NHS use for Astellas’ Xospata after rethinkNICE has recommended regular NHS funding for Astellas’ Xospata (gilteritinib) monotherapy for certain adult patients with acute myeloid leukaemia. In final draft guidance Share XNICE backs NHS use for Astellas’ Xospata after rethinkhttps://pharmaphorum.com/news/nice-backs-nhs-use-for-astellas-xospata-after-rethink/
Gilead trumpets data with newly-bought magrolimab in blood cancersJust three months after acquiring Forty Seven for $4.9 billion, Gilead has reported positive data on magrolimab, the Share XGilead trumpets data with newly-bought magrolimab in blood cancershttps://pharmaphorum.com/news/gilead-magrolimab-blood-cancer-asco/
New combination trial firms up Venclexta’s prospects in AMLAbbVie and Roche have been thrown a lifeline for their Venclexta drug in acute myeloid leukaemia (AML), just Share XNew combination trial firms up Venclexta’s prospects in AMLhttps://pharmaphorum.com/news/new-combination-trial-firms-up-venclextas-prospects-in-aml/
